IsoPlexis Corporation (NasdaqGM: ISO)

About IsoPlexis Corporation

IsoPlexis Corporation is a life sciences company dedicated to advancing the development of novel curative treatments and personalized therapeutics. The company's innovative offerings serve a wide international market, spanning North America (United States, Canada), numerous European nations (United Kingdom, Belgium, France, Czech Republic, Spain, Germany, Sweden, Italy, Switzerland), and key Asian and Pacific regions (Israel, China, Taiwan, Singapore, Japan, Australia, Korea). At its core, IsoPlexis provides a proprietary single-cell proteomics platform. This comprehensive system integrates specialized instruments, consumable chips, and advanced software, delivering an end-to-end solution for observing protein activity and function at the individual cellular level. Its instrument lineup includes the IsoLight and IsoSpark systems. For chip consumables, it offers IsoCode chips, designed for multiplexed single-cell functional proteomics, and CodePlex chips, which provide multiplexed analysis for ultra-low volume bulk samples. The IsoSpeak software further enhances the platform, providing robust dimensional data analysis and automating workflows through an intuitive, push-button user interface. This enables rapid, same-day visualization of both single-cell and bulk proteome data. Beyond its core products, IsoPlexis also extends research support and post-warranty services. Established in 2013, the company operates from its base in Branford, Connecticut.

ISIN

US4650051067

Founded

2013

Listed since

Oct 8, 2021

Exchange

Nasdaq Global Market

Currency

USD